Despite the lack of a dedicated kidney outcomes trial specifically investigating the reno-protective effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs), there is an ongoing clinical trial, FLOW, that aims to evaluate the kidney-protective effects of semaglutide in individuals with chronic kidney disease (CKD) and type 2 diabetes (T2D). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.